Otsuka Pharmaceutical

Otsuka Pharmaceutical's reported carbon emissions

Otsuka Pharmaceutical, headquartered in Japan and operating within the Pharmaceutical Preparation Manufacturing industry, has outlined a comprehensive strategy to address its carbon emissions and climate impact. For the reporting year 2024, Otsuka Pharmaceutical reported total global emissions of approximately 1,055,635,000 kg CO2e. This figure is comprised of Scope 1 emissions totalling about 368,733,000 kg CO2e, Scope 2 emissions of approximately 188,833,000 kg CO2e, and Scope 3 emissions amounting to around 698,157,000 kg CO2e. Significant contributors to their Scope 3 emissions include purchased goods and services, which accounted for approximately 698,157,000 kg CO2e. In 2023, the company's total global emissions were approximately 995,597,000 kg CO2e, with Scope 1 emissions at about 327,309,000 kg CO2e, Scope 2 at approximately 195,362,000 kg CO2e, and Scope 3 at around 664,646,000 kg CO2e. Otsuka Pharmaceutical has set ambitious climate targets. By 2028, the company aims for a 50% reduction in CO2 emissions across Scope 1 and Scope 2, using 2017 as the baseline year. This target was upgraded from previous goals in 2022. Looking further ahead, Otsuka Pharmaceutical has established a "Net Zero" vision for 2050, striving to reduce its total environmental impact across all business activities to zero. Their sustainability reports indicate progress towards these goals.